Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC).

被引：0

作者：

Clarke, Jeffrey Melson

Wang, Xiaofei F.

Gu, Lin

Stevenson, Marvaretta Miesha

Stinchcombe, Tom

Ramalingam, Sundhar

Antonia, Scott Joseph

Shariff, Afreen

Garst, Jennifer

Crawford, Jeffrey

Ready, Neal E.

机构：

[1] Duke Canc Inst, Durham, NC USA

[2] Duke Univ, Med Ctr, Durham, NC USA

[3] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC USA

[4] Duke Univ, Sch Med, Durham, NC USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e21683

引用

页数：2